Merck's Remigromig Trial Success Expands Ophthalmology Ambitions
Merck's (MRK) recent announcement of successful Phase 2b/3 clinical trial results for its investigational antibody remigromig has significant implications for the company's investment story. The BRUNELLO trial showed that remigromig matched ranibizumab on 52-week visual acuity outcomes in adults with diabetic macular edema, with both doses generally well-tolerated but higher rates of certain ocular adverse events.
This development highlights Merck's efforts to expand its retinal disease franchise beyond oncology and potentially broaden its future revenue mix across ophthalmology indications such as DME, neovascular age-related macular degeneration, and retinal vein occlusion. However, the mixed safety profile of remigromig reinforces that Merck's growth plan depends on successful execution of multiple pipeline assets.
Analysts' forecasts for Merck's revenue and earnings by 2029 range from $75.1 billion to $82.1 billion, with some estimates indicating potential upside from the current price. The company's narrative projects a significant increase in revenue and earnings over the next decade, assuming 4.1% yearly revenue growth and an earnings increase of about $19.2 billion from $3.2 billion today.